Irfan Asangani, PHD
Department of Experimental Therapeutics, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Experimental Therapeutics, Division Of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Associate Professor, The University of Texas MD Anderson Cancer Center, Houston, Texas
Research Interests
Research Areas: Cancer Biology, Molecular Biology, Transcription, Signaling pathways, Drug Resistance, Drug Repurposing
Research Projects:
Epigenetic Vulnerabilities in Cancer: Identifying and targeting epigenetic vulnerabilities in naïve and therapy-resistant cancer.
Metabolite Availability and Epigenetic Landscapes: Investigating how metabolic pathways influences epigenetic regulation in cancer.
Chromatin Dysregulation and Immune Surveillance: Exploring the role of chromatin modifiers and transcriptional regulators in immune surveillance and tumor progression.
Development of PhosTACs: Designing and developing PhosTACs (phosphorylation-targeting chimeras) as novel cancer therapeutics.
Education & Training
Degree-Granting Education
| 2009 | Heidelberg University/DKFZ, US, Cancer Biology, PhD |
| 2001 | Madras University, US, Biochemistry, Master Of Science |
| 1999 | Madras University, US, Biochemistry, Bachelor Of Science |
Postgraduate Training
| 2013-2015 | Research Investigator, University of Michigan |
| 2009-2012 | Postdoctoral Fellow, University of Michigan |
Experience & Service
Faculty Academic Appointments
Associate Professor, University of Pennsylvania, Philadelphia, Pennsylvania, 2023 - 2025
Assistant Professor, University of Pennsylvania, Philadelphia, Pennsylvania, 2015 - 2023
Other Professional Positions
Core Member, University of Pennsylvania, Philadelphia, Pennsylvania, 2015 - 2025
Associate Investigator, University of Pennsylvania, Philadelphia, Pennsylvania, 2015 - 2025
Member, University of Pennsylvania, Philadelphia, Pennsylvania, 2015 - 2025
Research Assistant, Indian Institute of Science, 2002 - 2004
Lecturer, Islamiah College, 2001 - 2002
Consultant roles, Zenith Epigenetics, Oncofusion Therapeutics
Extramural Institutional Committee Activities
Member, Technology Task Force (TTF) for Research Capital Equipment, The University of Texas MD Anderson Cancer Center, 2026 - Present
Committee Member, Prelim Advising Committee, Perelman School of Medicine, University of Pennsylvania, 2024 - 2025
Liaison, ACC Community Outreach and Engagement (COE), University of Pennsylvania, 2024 - 2025
Committee Chair, Cell and Molecular Biology (CAMB - Cancer Biology), Perelman School of Medicine, University of Pennsylvania, 2024 - 2025
Member, Search Committee, Michigan Center for Translational Pathology (MCTP), University of Michigan, 2024 - 2025
Member for Hamza Turkistani, Thesis Committee, School of Engineering and Applied Sciences, University of Pennsylvania, 2023 - 2026
Diversity Search Adviser, Diversity Search, Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, 2023 - 2025
Member for Amy Gladstein, Thesis Committee, Perelman School of Medicine, University of Pennsylvania, 2023 - 2025
Prelim Committee Member, Committee Member -, Perelman School of Medicine, University of Pennsylvania, 2021 - Present
Co-Chair, Search Committee, Department of Cancer Biology, University of Pennsylvania, 2021 - 2025
Member for Benjamin Caiello, Thesis Committee, Perelman School of Medicine, University of Pennsylvania, 2021 - 2023
Committee Member, Prelim Committee, Perelman School of Medicine at the University of Pennsylvania, 2019 - Present
Committee Member, Thesis Committee for Nelson Freeburg, Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, 2019 - 2023
Committee Member, Thesis Committee for Zvi Cramer, Cancer Biology Graduate Group, Perelman School of Medicine, University of Pennsylvania, 2019 - 2023
Committee Member, Prelim Committee, Perelman School of Medicine at the University of Pennsylvania, 2018 - Present
Committee Member, Thesis Committee for Grant Grothusen, Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, 2018 - 2023
Committee Member, Thesis Committee for Jonuelle Acosta, Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, 2018 - 2023
Committee Member, Thesis Committee for Yekaterina Kori, Biochemistry and Molecular Biophysics Graduate Group,, Perelman School of Medicine, University of Pennsylvania, 2018 - 2021
Member, Prelim Committee, Perelman School of Medicine at the University of Pennsylvania, 2017 - Present
Committee Member, Cancer Biology Student Advising Committee, Perelman School of Medicine, University of Pennsylvania, 2017 - 2025
Member, Admissions Committee, Perelman School of Medicine, University of Pennsylvania, 2017 - 2025
Member, Seminar Committee, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, 2017 - 2022
Member, Thesis Committee for Qiaosi Tang, Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, 2017 - 2021
Member, Thesis Committee for Dylan Marchione, Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, 2017 - 2020
Member, Thesis Committee for Michael Werner, Department of Immunology, Perelman School of Medicine, University of Pennsylvania, 2017 - 2020
Member, Thesis Committee for Salina Yuan, MD-PhD, Department of Cancer Biology,, Perelman School of Medicine, University of Pennsylvania, 2017 - 2020
Member, Thesis Committee for David Walter, Cell and Molecular Biology - Cancer Biology, Perelman School of Medicine, University of Pennsylvania, 2017 - 2020
Member, Search Committee, Perelman School of Medicine, University of Pennsylvania, 2015 - 2025
Participating Member, Precision Medicine Sequencing Tumor Board, MI-Oncoseq, Michigan Center for Translational Pathology (MCTP), University of Michigan, 2012 - 2015
Editorial Activities
Guest Editor, BioMed Research International, 2014 - Present
Reviewer, Reviewer for Nature, Nature Genetics, Nature Cancer, Cancer Discovery, Nature Communications, Science Advances, JCI, Nature Drug Discovery, Elife, European Urology, Epigenetics & Chromatin, Cancer, Prostate, Cell Reports, Epigenetics & Chromatin, Cancer Research, Clinical Cancer Research, Molecular Cancer Research, Journal of Experimental Medicine, BMC Genomics, BMC Cancer, Oncogene, British Journal of Cancer, Neoplasia, International Journal of Cancer, 2009 - Present
Honors & Awards
| 2026 - 2031 | CPRIT Rising Star Recruitment Award |
| 2023 - 2026 | Research Scholar Award, American Cancer Society |
| 2021 - Present | SBUR Young Investigator Award, Society for Basic Urologic Research |
| 2020 - 2022 | Conquer Cancer Now Award, Concern Foundation |
| 2020 - 2021 | STL Cure Sarcoma Research Award, Sarcoma Foundation of America |
| 2017 - Present | Breakthrough Bike Challenge - Cooper Scholar Award |
| 2017 - Present | AFCRI Pilot Award for New Investigators, Abramson Family Cancer Research Institute, University of Pennsylvania |
| 2014 - Present | Best Poster Award, 7th Annual Prostate Cancer Program Retreat |
| 2014 - 2018 | K99/R00 Pathway to Independence Award, NIH |
| 2013 - Present | Millennium Scholar-In-Training Award, American Association for Cancer Research |
| 2013 - Present | Challenge Award, Prostate Cancer Foundation |
| 2013 - Present | Young Investigator Award, Prostate Cancer Foundation |
| 2012 - Present | Best Poster Award, 5th Annual Prostate Cancer Program Retreat |
| 2010 - Present | DAAD Travel Grant to attend the DKFZ Alumni Meeting, Klinikum Mannheim / DKFZ / Heidelberg University, Germany |
| 2008 - Present | Best Poster Award, 5th Colmar Scientific Symposium "The New RNA Frontiers". Colmar, France |
| 2007 - Present | Invited Young Researcher, Lindau Nobel Laureate Meeting, Lindau, Germany |
| 2007 - Present | Invited to represent DKFZ graduate students at Berlin-Summer School, Berlin, Germany |
| 2006 - Present | Best Participant Award, Ambion/Applied biosystems/EMBL miRNA Workshop, Heidelberg, Germany |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2023. Department of Experimental Therapeutics Seminar. Invited.
Regional Presentations
- 2025. Conference: BASSER Annual Symposium. Invited.
- 2025. Conference: ACC Mini Symposium. Invited.
- 2025. Conference: Biochemistry and Molecular Biology Department Seminar. Invited.
- 2024. Conference: Basser Center for BRCA Noon Conference. Invited.
- 2022. Conference: 10th Clinical Translation of Epigenetics in Cancer Therapy. Invited.
- 2019. Conference: Basser Center for BRCA Noon Conference. Invited.
- 2018. Epigenetic Vulnerabilities in Castration-Resistant Prostate Cancer. Conference: Prostate Cancer Working Group Meeting.
- 2017. Conference: Sidney Kimmel Cancer Centers’ Prostate Cancer Amtrak Alliance Summit. Invited.
National Presentations
- 2025. Center for Prostate Disease Research (CPDR) Scientific Retreat. Invited.
- 2025. Conference: O’Neal Cancer Center Seminar Series. Invited. Tuscaloosa, Alabama, US.
- 2023. Conference: AACR Special Conference on Advances in Prostate Cancer Research. Invited.
- 2022. Conference: Center of Excellence for Prostate Cancer Lecture. Invited.
- 2022. Conference: Biochemistry and Molecular Biology Department Seminar. Invited.
- 2021. Conference: Society for Basic Urology Research (SBUR) Annual Meeting. Invited.
- 2021. Conference: EpiCypher 2021: Biological and Clinical Frontiers in Epigenetics. Invited.
- 2021. Conference: Topics in Cancer Seminar Series. Invited.
- 2021. Conference: Eppley Institute Seminar Series. Invited.
- 2020. Therapeutic targeting of TMPRSS2 and ACE2 as a potential strategy to combat COVID-19. Invited. AACR Virtual Meeting: COVID-19 and Cancer.
- 2019. Prostate Cancer Foundation (PCF) Webinar. Invited.
International Presentations
- 2025. EpiCypher 2025: Biological and Clinical Frontiers in Epigenetics Conference. Invited.
- 2024. TMCS 2024 – International Conference on Tumor Microenvironment and Cellular Stress. Invited.
- 2024. Genome Regulation through RNA Conference. Invited.
- 2023. 9th International Conference on Tumor Microenvironment and Cellular Stress. Invited.
- 2023. Biochemistry and Molecular Biology Department Seminar. Invited. Odense, DK.
- 2023. Conference: Seminar. Invited.
- 2023. Conference: Sarcoma Biology Virtual Club Meeting. Invited.
- 2023. Conference: Seminar.
- 2023. Targeting transcriptional regulation in prostate cancer. Invited. European Association for Cancer Research (EACR) Meeting.
- 2022. Cancer and Stem Cell (CSCB) Seminar Series. Invited.
- 2022. Epigenetic vulnerabilities in prostate cancer. Invited. International Cancer Epigenetics Conference.
- 2021. Conference: Invited Lecture. Invited.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | The role of NNMT in prostate cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2026 - 2031 |
| Title: | Innovative organometallic complexes to stably harness auger- and alpha-emitting radioisotopes |
| Funding Source: | Welch Foundation |
| Role: | Co-I |
| Date: | 2026 - 2031 |
| Title: | CPRIT Rising Star Recruitment Grant |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | PI |
| Date: | 2025 - 2030 |
| Title: | Metabolic compartmentalization and regulation of histone propionylation |
| Funding Source: | National Institutes of Health, National Cancer Institute |
| Role: | Co-I |
| ID: | R01CA292937 |
| Date: | 2025 - 2030 |
| Title: | NIH-NCI Epigenetic targets in prostate cancer |
| Funding Source: | National Institutes of Health (NIH), National Cancer Institute (NCI) |
| Role: | PI |
| ID: | R01CA299870 |
| Date: | 2025 - 2030 |
| Title: | Towards Characterization of Epigenetic targets in Prostate Cancer |
| Funding Source: | NIH NCI |
| Role: | PI |
| ID: | R01CA299870-01 |
| Date: | 2025 - 2025 |
| Title: | Leveraging Targeted Genome Instability to Transform Immune-Cold Prostate Cancer into an Immune-Responsive State |
| Funding Source: | Abramson Cancer Center |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | BASSER Center for BRCA 2024 grant |
| Funding Source: | Basser Center for BRCA, University of Pennsylvania |
| Role: | Co-PI |
| Date: | 2023 - 2026 |
| Title: | Role of glutamine metabolism in dendritic cell development |
| Funding Source: | National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases |
| Role: | Co-I |
| Date: | 2023 - 2025 |
| Title: | Ewing Sarcoma, Sarcoma Program |
| Funding Source: | Abramson Cancer Center |
| Role: | PI |
| Date: | 2023 - 2025 |
| Title: | Discovery and characterization of exceptionally specific surface oncoprotein LIPI in Ewing Sarcoma |
| Funding Source: | NIH-NCI |
| Role: | PI |
| ID: | R21CA274009 |
| Date: | 2023 - 2025 |
| Title: | BASSER Center for BRCA 2023 grant |
| Funding Source: | Basser Center for BRCA, University of Pennsylvania |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | Effect of DNA repeat silencing on efficacy of ATRi in prostate cancer treatment |
| Funding Source: | National Institutes of Health, National Cancer Institute |
| Role: | Co-I |
| ID: | R01CA266645 |
| Date: | 2023 - 2026 |
| Title: | Oncofusion triggered opportunistic de novo enhancer assembly activates novel therapeutic targets in Ewing Sarcoma |
| Funding Source: | American Cancer Society (ACS), Research Scholar Award |
| Role: | PI |
| Date: | 2021 - 2025 |
| Title: | PP2A activation as a therapy for AR addicted refractory castration-resistant prostate cancer |
| Funding Source: | U.S. Department of Defense |
| Role: | PI |
| Date: | 2021 - 2022 |
| Title: | Repeat transcriptional deregulation combined with ATRi as a treatment for prostate cancer |
| Funding Source: | AFCRI Pilot Award |
| Role: | PI |
| Date: | 2020 - 2022 |
| Title: | Conquer Cancer Now Award |
| Funding Source: | Concern Foundation |
| Role: | PI |
| Date: | 2020 - 2022 |
| Title: | Evaluating the efficacy of CDK7 inhibitor CT7001 in clinically relevant CRPC models |
| Funding Source: | Carrick Therapeutics |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | EWS-FLI1 triggered opportunistic de novo enhancer assembly activates potential cellular therapy targets in Ewing Sarcoma |
| Funding Source: | Sarcoma Foundation of America |
| Role: | PI |
| Date: | 2020 - 2026 |
| Title: | Role of MED1 in the AR-dependent transcription in advanced prostate cancer |
| Funding Source: | National Institutes of Health, National Cancer Institute |
| Role: | PI |
| ID: | R01CA249210 |
| Date: | 2019 - 2020 |
| Title: | Identifying mechanisms of action of CBP/P300- BET bromodomain dual inhibitor on AR signaling in enzalutamide-resistant prostate cancer |
| Funding Source: | Epigene Therapeutics Inc |
| Role: | PI |
| Date: | 2019 - 2020 |
| Title: | High throughput screening of FDA approved drugs with EZH2 inhibitor in prostate cancer cells |
| Funding Source: | Epigenetics Pilot Project, Penn Epigenetics Institute |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Abramson Family Cancer Research (AFCRI) Pilot Award |
| Funding Source: | Abramson Family Cancer Research |
| Role: | Co-PI |
| Date: | 2018 - 2019 |
| Title: | Ewing Sarcoma donor gift, Family of Kim Hayman |
| Funding Source: | Ewing Sarcoma Donor |
| Role: | PI |
| Date: | 2017 - 2018 |
| Title: | Investigating the molecular mechanisms of acquired resistance to BET bromodomain inhibitors in castration-resistant prostate cancer |
| Funding Source: | Abramson Cancer Center |
| Role: | PI |
| Date: | 2017 - 2020 |
| Title: | Investigating the molecular mechanisms of acquired resistance to BET bromodomain inhibitors in castration-resistant prostate cancer |
| Funding Source: | Department of Defense |
| Role: | PI |
| ID: | W81XWH-17-1-0404 |
| Date: | 2017 - 2018 |
| Title: | Research Award |
| Funding Source: | BASSER Center for BRCA |
| Role: | PI |
| Date: | 2017 - 2019 |
| Title: | Scientific Research Agreement |
| Funding Source: | Zenith Epigenetics |
| Role: | PI |
| Date: | 2017 - 2017 |
| Title: | Breakthrough Bike Challenge |
| Funding Source: | Cooper Scholar Award |
| Role: | PI |
| Date: | 2017 - 2017 |
| Title: | High throughput screening of FDA approved drugs with EZH2 inhibitor in prostate cancer cells |
| Funding Source: | Epigenetics Institute Award, Penn Epigenetics Institute |
| Role: | PI |
| Date: | 2015 - 2018 |
| Title: | Characterization of Epigenetic Targets in Prostate Cancer |
| Funding Source: | National Cancer Institute/NIH |
| Role: | PI |
| ID: | 5R00-CA187664 |
| Date: | 2014 - 2015 |
| Title: | Characterization of Epigenetic Targets in Prostate Cancer |
| Funding Source: | National Cancer Institute/NIH |
| Role: | PI |
| ID: | 1K99CA187664-01 |
| Date: | 2013 - 2016 |
| Title: | Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer |
| Funding Source: | https://ror.org/01npwtv09 |
| Role: | Key |
| Date: | 2013 - 2016 |
| Title: | Characterization and therapeutic targeting of MMSET in prostate cancer |
| Funding Source: | Prostate Cancer Foundation, Young Investigator Award |
| Role: | PI |
| Title: | Role of NSD2 in mediating AR signaling in metastatic prostate cancer |
| Funding Source: | AstraZeneca |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Gladstein AC, Poltorack CD, Solomon AMC, Venkatesh S, Adler KM, Robertson MR, Stransky S, Irizarry-Negron VM, Ruiz DA, Freeburg NF, Sidoli S, Asangani IA, Shaffer SM, Feldser DM. The H3 (K36M) oncohistone inhibits NSD2 to activate a SETD2-dependent antiviral-like immune response in KRAS-driven lung cancer. bioRxiv, 2025. e-Pub 2025. PMID: 40501771.
- Sussman JH, Cure HW, Yuan S, Ito K, Asangani IA, Garcia BA, Stanger BZ, Katsuda T. In vivo CRISPR screening reveals epigenetic regulators of hepatobiliary plasticity. Genes Dev 39(9-10):603-616, 2025. e-Pub 2025. PMID: 40169232.
- Blanchard T, Faridi P, Xu C, Bear AS, Rasool RU, Huang G, Lim TCC, Ayala R, Gabunia K, Ji M, Posey AD Jr, Scholler J, Asangani IA, Purcell AW, Linette GP, June CH, Carreno BM. LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma. Sci Rep 15(1):13007, 2025. e-Pub 2025. PMID: 40234527.
- Schwab A, Siddiqui MA, Ramesh V, Gollavilli PN, Turtos AM, Moller SS, Pinna L, Havelund JF, Romer AMA, Ersan PG, Parma B, Marschall S, Dettmer K, Alhusayan M, Bertoglio P, Querzoli G, Mielenz D, Sahin O, Faergeman NJ, Asangani IA, Ceppi P. Polyol pathway-generated fructose is indispensable for growth and survival of non-small cell lung cancer. Cell Death Differ 32(4):587-597, 2025. e-Pub 2025. PMID: 39567724.
- Parolia A, Eyunni S, Verma BK, Young E, Liu Y, Liu L, George J, Aras S, Das CK, Mannan R, Ur Rasool R, Mitchell-Velasquez E, Mahapatra S, Luo J, Carson SE, Xiao L, Gajjala PR, Venkatesh S, Jaber M, Wang X, He T, Qiao Y, Pang M, Zhang Y, Tien JC, Louw M, Alhusayan M, Cao X, Su F, Tavana O, Hou C, Wang Z, Ding K, Chinnaiyan AM, Asangani IA. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis. Nat Genet 56(10):2132-2143, 2024. e-Pub 2024. PMID: 39251788.
- Parolia A, Eyunni S, Verma BK, Young E, Liu L, George J, Aras S, Das CK, Mannan R, Rasool RU, Luo J, Carson SE, Mitchell-Velasquez E, Liu Y, Xiao L, Gajjala PR, Jaber M, Wang X, He T, Qiao Y, Pang M, Zhang Y, Alhusayan M, Cao X, Tavana O, Hou C, Wang Z, Ding K, Chinnaiyan AM, Asangani IA. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis. bioRxiv, 2024. e-Pub 2024. PMID: 38464251.
- Katsuda T, Sussman JH, Ito K, Katznelson A, Yuan S, Takenaka N, Li J, Merrell AJ, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ. Cellular reprogramming in vivo initiated by SOX4 pioneer factor activity. Nat Commun 15(1):1761, 2024. e-Pub 2024. PMID: 38409161.
- Rasool RU, O'Connor CM, Das CK, Alhusayan M, Verma BK, Islam S, Frohner IE, Deng Q, Mitchell-Velasquez E, Sangodkar J, Ahmed A, Linauer S, Mudrak I, Rainey J, Zawacki KP, Suhan TK, Callahan CG, Rebernick R, Natesan R, Siddiqui J, Sauter G, Thomas D, Wang S, Taylor DJ, Simon R, Cieslik M, Chinnaiyan AM, Busino L, Ogris E, Narla G, Asangani IA. Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance. Nat Commun 14(1):5253, 2023. e-Pub 2023. PMID: 37644036.
- Walter DM, Gladstein AC, Doerig KR, Natesan R, Baskaran SG, Gudiel AA, Adler KM, Acosta JO, Wallace DC, Asangani IA, Feldser DM. Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling. Commun Biol 6(1):255, 2023. e-Pub 2023. PMID: 36899051.
- Katsuda T, Sussman J, Ito K, Katznelson A, Yuan S, Li J, Merrell AJ, Takenaka N, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ. Physiological reprogramming in vivo mediated by Sox4 pioneer factor activity. bioRxiv, 2023. e-Pub 2023. PMID: 36824858.
- Deng Q, Natesan R, Cidre-Aranaz F, Arif S, Liu Y, Rasool RU, Wang P, Mitchell-Velasquez E, Das CK, Vinca E, Cramer Z, Grohar PJ, Chou M, Kumar-Sinha C, Weber K, Eisinger-Mathason TSK, Grillet N, Grunewald TGP, Asangani IA. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1. Cell Rep 39(11):110971, 2022. e-Pub 2022. PMID: 35705030.
- Deng Q, Rasool RU, Russell RM, Natesan R, Asangani IA. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. iScience 24(3):102254, 2021. e-Pub 2021. PMID: 33681723.
- Gollavilli PN, Parma B, Siddiqui A, Yang H, Ramesh V, Napoli F, Schwab A, Natesan R, Mielenz D, Asangani IA, Brabletz T, Pilarsky C, Ceppi P. The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter. Oncogene 40(12):2309-2322, 2021. e-Pub 2021. PMID: 33654197.
- Siddiqui MA, Gollavilli PN, Ramesh V, Parma B, Schwab A, Vazakidou ME, Natesan R, Saatci O, Rapa I, Bironzo P, Schuhwerk H, Asangani IA, Sahin O, Volante M, Ceppi P. Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. Br J Cancer 124(1):281-289, 2021. e-Pub 2021. PMID: 33024270.
- Chen J, Harding SM, Natesan R, Tian L, Benci JL, Li W, Minn AJ, Asangani IA, Greenberg RA. Cell Cycle Checkpoints Cooperate to Suppress DNA- and RNA-Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses. Cell Rep 32(9):108080, 2020. e-Pub 2020. PMID: 32877684.
- Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjostrom M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. The DNA methylation landscape of advanced prostate cancer. Nat Genet 52(8):778-789, 2020. e-Pub 2020. PMID: 32661416.
- Yuan S, Natesan R, Sanchez-Rivera FJ, Li J, Bhanu NV, Yamazoe T, Lin JH, Merrell AJ, Sela Y, Thomas SK, Jiang Y, Plesset JB, Miller EM, Shi J, Garcia BA, Lowe SW, Asangani IA, Stanger BZ. Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression. Cancer Discov 10(6):854-871, 2020. e-Pub 2020. PMID: 32188706.
- Devalaraja S, To TKJ, Folkert IW, Natesan R, Alam MZ, Li M, Tada Y, Budagyan K, Dang MT, Zhai L, Lobel GP, Ciotti GE, Eisinger-Mathason TSK, Asangani IA, Weber K, Simon MC, Haldar M. Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression. Cell 180(6):1098-1114.e16, 2020. e-Pub 2020. PMID: 32169218.
- Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, Pluim D, Coggins S, Saatci O, Annaratone L, Hm Schellens J, Kim B, Asangani IA, Rasheed SAK, Marchio C, Sahin O, Ceppi P. Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. Cell Death Differ 26(11):2223-2236, 2019. e-Pub 2019. PMID: 30737477.
- Rasool RU, Natesan R, Deng Q, Aras S, Lal P, Sander Effron S, Mitchell-Velasquez E, Posimo JM, Carskadon S, Baca SC, Pomerantz MM, Siddiqui J, Schwartz LE, Lee DJ, Palanisamy N, Narla G, Den RB, Freedman ML, Brady DC, Asangani IA. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discov 9(11):1538-1555, 2019. e-Pub 2019. PMID: 31466944.
- Kregel S, Malik R, Asangani IA, Wilder-Romans K, Rajendiran T, Xiao L, Vo JN, Soni T, Cieslik M, Fernadez-Salas E, Zhou B, Cao X, Speers C, Wang S, Chinnaiyan AM. Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res 25(13):4038-4048, 2019. e-Pub 2019. PMID: 30918020.
- Gollavilli PN, Pawar A, Wilder-Romans K, Natesan R, Engelke CG, Dommeti VL, Krishnamurthy PM, Nallasivam A, Apel IJ, Xu T, Qin ZS, Feng FY, Asangani IA. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins. Cancer Res 78(16):4760-4773, 2018. e-Pub 2018. PMID: 29898995.
- Chakravarthi BVSK, Chandrashekar DS, Agarwal S, Balasubramanya SAH, Pathi SS, Goswami MT, Jing X, Wang R, Mehra R, Asangani IA, Chinnaiyan AM, Manne U, Sonpavde G, Netto GJ, Gordetsky J, Varambally S. miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. Mol Cancer Res 16(7):1125-1137, 2018. e-Pub 2018. PMID: 29025958.
- Pawar A, Gollavilli PN, Wang S, Asangani IA. Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. Cell Rep 22(9):2236-2245, 2018. e-Pub 2018. PMID: 29490263.
- Stypulkowski E, Asangani IA, Witze ES. The depalmitoylase APT1 directs the asymmetric partitioning of Notch and Wnt signaling during cell division. Sci Signal 11(511), 2018. e-Pub 2018. PMID: 29295957.
- Wang X, Qiao Y, Asangani IA, Ateeq B, Poliakov A, Cieslik M, Pitchiaya S, Chakravarthi BVSK, Cao X, Jing X, Wang CX, Apel IJ, Wang R, Tien JC, Juckette KM, Yan W, Jiang H, Wang S, Varambally S, Chinnaiyan AM. Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell 31(4):532-548.e7, 2017. e-Pub 2017. PMID: 28344039.
- Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Mol Cancer Res 14(4):324-31, 2016. e-Pub 2016. PMID: 26792867.
- Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, Ning Y, Su F, Wang R, Stoffel EM, Innis JW, Roberts JS, Robertson PL, Yanik G, Chamdin A, Connelly JA, Choi S, Harris AC, Kitko C, Rao RJ, Levine JE, Castle VP, Hutchinson RJ, Talpaz M, Robinson DR, Chinnaiyan AM. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA 314(9):913-25, 2015. e-Pub 2015. PMID: 26325560.
- Powell K, Semaan L, Conley-LaComb MK, Asangani I, Wu YM, Ginsburg KB, Williams J, Squire JA, Maddipati KR, Cher ML, Chinni SR. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clin Cancer Res 21(11):2569-79, 2015. e-Pub 2015. PMID: 25754347.
- Scanlon CS, Banerjee R, Inglehart RC, Liu M, Russo N, Hariharan A, van Tubergen EA, Corson SL, Asangani IA, Mistretta CM, Chinnaiyan AM, D'Silva NJ. Galanin modulates the neural niche to favour perineural invasion in head and neck cancer. Nat Commun 6:6885, 2015. e-Pub 2015. PMID: 25917569.
- Malik R, Khan AP, Asangani IA, Cieslik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, Stender R, Wu YM, Niknafs YS, Jing X, Qiao Y, Palanisamy N, Kunju LP, Krishnamurthy PM, Yocum AK, Mellacheruvu D, Nesvizhskii AI, Cao X, Dhanasekaran SM, Feng FY, Grembecka J, Cierpicki T, Chinnaiyan AM. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med 21(4):344-52, 2015. e-Pub 2015. PMID: 25822367.
- Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, Carley A, Niknafs YS, Sahu A, Han S, Ma T, Liu M, Asangani IA, Jing X, Cao X, Dhanasekaran SM, Robinson DR, Feng FY, Chinnaiyan AM. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res 12(8):1081-7, 2014. e-Pub 2014. PMID: 25030374.
- Alluri PG, Asangani IA, Chinnaiyan AM. BETs abet Tam-R in ER-positive breast cancer. Cell Res 24(8):899-900, 2014. e-Pub 2014. PMID: 25001387.
- Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510(7504):278-82, 2014. e-Pub 2014. PMID: 24759320.
- Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY, Chinnaiyan AM. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget 5(6):1434-8, 2014. e-Pub 2014. PMID: 24727738.
- Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, Chen W, Han S, Jing X, Cao X, Wang X, Chandler B, Yan W, Siddiqui J, Kunju LP, Dhanasekaran SM, Pienta KJ, Feng FY, Chinnaiyan AM. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 45(11):1392-8, 2013. e-Pub 2013. PMID: 24076601.
- Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A, Chinnaiyan AM. The role of sarcosine metabolism in prostate cancer progression. Neoplasia 15(5):491-501, 2013. e-Pub 2013. PMID: 23633921.
- Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, Mehra R, Lonigro RJ, Siddiqui J, Palanisamy N, Wu YM, Cao X, Kim JH, Zhao M, Qin ZS, Iyer MK, Maher CA, Kumar-Sinha C, Varambally S, Chinnaiyan AM. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell 49(1):80-93, 2013. e-Pub 2013. PMID: 23159737.
- Wang R, Asangani IA, Chakravarthi BV, Ateeq B, Lonigro RJ, Cao Q, Mani RS, Camacho DF, McGregor N, Schumann TE, Jing X, Menawat R, Tomlins SA, Zheng H, Otte AP, Mehra R, Siddiqui J, Dhanasekaran SM, Nyati MK, Pienta KJ, Palanisamy N, Kunju LP, Rubin MA, Chinnaiyan AM, Varambally S. Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia 14(10):905-14, 2012. e-Pub 2012. PMID: 23097625.
- Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, Fullen DR, Johnson TM, Giordano TJ, Palanisamy N, Chinnaiyan AM. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 3(9):1011-25, 2012. e-Pub 2012. PMID: 22948084.
- Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239-43, 2012. e-Pub 2012. PMID: 22722839.
- Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, Robinson DR, Wu YM, Cao X, Asangani IA, Kothari V, Prensner JR, Lonigro RJ, Iyer MK, Barrette T, Shanmugam A, Dhanasekaran SM, Palanisamy N, Chinnaiyan AM. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell 149(7):1622-34, 2012. e-Pub 2012. PMID: 22726445.
- Leupold JH, Asangani IA, Mudduluru G, Allgayer H. Promoter cloning and characterization of the human programmed cell death protein 4 (pdcd4) gene: evidence for ZBP-89 and Sp-binding motifs as essential Pdcd4 regulators. Biosci Rep 32(3):281-97, 2012. e-Pub 2012. PMID: 22111549.
- Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis-Filho JS, Kumar-Sinha C, Chinnaiyan AM. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 17(12):1646-51, 2011. e-Pub 2011. PMID: 22101766.
- Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, Wang R, Li Y, Dahiya A, Wang L, Pandhi M, Lonigro RJ, Wu YM, Tomlins SA, Palanisamy N, Qin Z, Yu J, Maher CA, Varambally S, Chinnaiyan AM. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 20(2):187-99, 2011. e-Pub 2011. PMID: 21840484.
- Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, Cao X, Jing X, Wang X, Siddiqui J, Wei JT, Robinson D, Iyer HK, Palanisamy N, Maher CA, Chinnaiyan AM. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29(8):742-9, 2011. e-Pub 2011. PMID: 21804560.
- Mudduluru G, George-William JN, Muppala S, Asangani IA, Kumarswamy R, Nelson LD, Allgayer H. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci Rep 31(3):185-97, 2011. e-Pub 2011. PMID: 20815812.
- Wang XS, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, Robinson D, Cao Q, Prensner JR, Yocum AK, Wang R, Fries DF, Han B, Asangani IA, Cao X, Li Y, Omenn GS, Pflueger D, Gopalan A, Reuter VE, Kahoud ER, Cantley LC, Rubin MA, Palanisamy N, Varambally S, Chinnaiyan AM. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov 1(1):35-43, 2011. e-Pub 2011. PMID: 22140652.
- Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19(5):664-78, 2011. e-Pub 2011. PMID: 21575865.
- Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 3(72):72ra17, 2011. e-Pub 2011. PMID: 21368222.
- Rasheed SA, Efferth T, Asangani IA, Allgayer H. First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 127(6):1475-85, 2010. e-Pub 2010. PMID: 20232396.
- Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res 69(6):2461-70, 2009. e-Pub 2009. PMID: 19276367.
- Limaye AM, Asangani I, Kalyani T, Kondaiah P. Changes in gene expression following androgen receptor blockade is not equivalent to androgen ablation by castration in the rat ventral prostate. J Biosci 33(2):209-20, 2008. e-Pub 2008. PMID: 18535355.
- Asangani IA, Rasheed SA, Leupold JH, Post S, Allgayer H. NRF-1, and AP-1 regulate the promoter of the human calpain small subunit 1 (CAPNS1) gene. Gene 410(1):197-206, 2008. e-Pub 2008. PMID: 18234454.
- Limaye AM, Asangani I, Bora N, Kondaiah P. Novel flutamide regulated genes in the rat ventral prostate: differential modulation of their expression by castration and flutamide treatments. Asian J Androl 9(6):801-8, 2007. e-Pub 2007. PMID: 17968466.
- Leupold JH, Asangani I, Maurer GD, Lengyel E, Post S, Allgayer H. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. Mol Cancer Res 5(5):485-96, 2007. e-Pub 2007. PMID: 17510314.
- Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer H. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res 11(24 Pt 1):8538-48, 2005. e-Pub 2005. PMID: 16361535.
- Deng Q, Mitchell-Velásquez E, Venkatesh S, Mannan R, Cho H, Alhusayan M, Yashfeen A, Natesan R, Bhanu NV, Paturu R, Siddique J, Mehra R, Varambally S, Garcia B, Feldser D, Lal P, Chinnaiyan AM, Asangani IA. NNMT Loss Drives Cancer Progression by enhancing SAM availability for mTORC1 Signaling and Chromatin Methylation. bioRxiv. PMID: 42553046.
Review Articles
- Asangani I, Blair IA, Van Duyne G, Hilser VJ, Moiseenkova-Bell V, Plymate S, Sprenger C, Wand AJ, Penning TM. Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer. J Biol Chem 296:100240, 2021. e-Pub 2021. PMID: 33384381.
- Penning TM, Asangani IA, Sprenger C, Plymate S. Intracrine androgen biosynthesis and drug resistance. Cancer Drug Resist 3(4):912-929, 2020. e-Pub 2020. PMID: 35582223.
- Natesan R, Aras S, Effron SS, Asangani IA. Epigenetic Regulation of Chromatin in Prostate Cancer. Adv Exp Med Biol 1210:379-407, 2019. e-Pub 2019. PMID: 31900918.
Other Articles
- Amara CS, Piyarathna DWB, Kamal AHM, Chan YS, Kami Reddy KR, Ambati CSR, Hassan MK, Shriwas P, Gandhi T, Jain A, Gangnus T, Popli P, Borkar R, Kang SW, Summers SL, Putluri V, Grimm SL, Venkatesh S, Song N, Seeley EH, Hedlich-Dwyer J, Chen SH, Mahajan NP, Jain AK, Dobrolecki LE, Wells GA, Villanueva H, Li J, Liu X, Bollag RJ, Malovannaya A, Jung SY, Lee HS, Asangani Irfan, Terris MK, Creighton CJ, Ballester LY, Karanam B, Liu S, Lee M, Raju RR, Siddiqui MM, Eberlin LS, Kommagani R, Sreekumar A, Gao J, Young NL, Hodges HC, Coarfa C, Gassman NR, Lerner SP, Lotan Y Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression. Cancer Lett 653:218562, 2026. PMID: 42092682.
- Demetriadou C, Noji M, Good AL, Mitchell-Velasquez E, Venkatesh S, Kantner DS, Pennise J, Costa-Pinheiro P, Pinheiro LV, Harada T, Nguyen PTT, Chatoff A, Megill E, Crispim CVDS, Marcinkiewicz MM, Meier JL, Arany Z, Asangani Irfan, Furth EE, Stanger BZ, Snyder NW, Wellen KE A nuclear branched-chain amino acid catabolism pathway controls histone propionylation in pancreatic cancer. bioRxiv, 2025. PMID: 40568091.
Editorials
- Rasool RU, Natesan R, Asangani IA. Toppling the HAT to Treat Lethal Prostate Cancer. Cancer Discov 11(5):1011-1013, 2021. PMID: 33947717.
- Asangani IA, Chinnaiyan AM. BETting on a new prostate cancer treatment. Cell Cycle 13(13):2015-6, 2014. PMID: 24905827.
Patents
- Wang, Ran, Zhao, Yang, Liu, Bai, McEachern, Stuckey, Meagher, Sun, Li, Zhou, Karatas, Luo, Chinnaiyan, Asangani Irfan. BET bromodomain inhibitors and therapeutic methods using the same, 2014. Patent Number: WO2014164596 A1.
- Wang, Ran, Zhao, Yang, Liu, Bai, McEachern, Stuckey, Meagher, Sun, Li, Zhou, Karatas, Luo, Chinnaiyan, Asangani Irfan. BET bromodomain inhibitors for treating prostate cancer and breast cancer. Patent Number: 61/946,501.
- Chinnaiyan, Varambally, Cao, Asangani Irfan. Compositions and methods for inhibiting MMSET. Patent Number: 8,697,407 B2.
- Wang, Zhao, Aguliar, Liu, Bai, McEachern, Sun, Wen, Luo, Zhao, Chinnaiyan, Asangani Irfan, Stuckey, Meagher, Ran, Hu. 9H-pyrimido [4,5-b] indoles and related analogs as BET bromodomain inhibitors. Patent Number: 10253044.
Patient Reviews
CV information above last modified August 28, 2026